Nuvaira, Inc., founded in Plymouth, United States, is dedicated to improving the lives of patients with obstructive lung diseases through innovative medical devices. Their core mission is to enhance breathing and reduce the frequency and severity of COPD exacerbations. The company's flagship product, the dNerva® Lung Denervation System, is a catheter-based system designed to treat overactive airways. This one-time, outpatient procedure aims to provide continuous bronchodilation and whole lung treatment, targeting a global market of COPD patients.
Nuvaira has garnered attention from notable investors and medical professionals in the respiratory care field. The company has achieved significant milestones, including successful clinical trials demonstrating the efficacy of their dNerva® system in reducing COPD exacerbations. Nuvaira's impact on the medical community is substantial, offering a novel therapeutic option that promises to improve patient outcomes and quality of life for those suffering from chronic obstructive pulmonary disease worldwide.
